Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

120 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Editorial: Cutting edge basic and clinical bladder cancer research - the IBCN updates.
Goebell PJ, Kamat AM, Black PC, Dyrskjøt L, Nawroth R, Seiler R, Todenhöfer T, Williams SB, Schmitz-Dräger BJ. Goebell PJ, et al. Among authors: schmitz drager bj. Urol Oncol. 2023 Jul;41(7):313-317. doi: 10.1016/j.urolonc.2022.12.013. Epub 2023 Jan 13. Urol Oncol. 2023. PMID: 36641302 No abstract available.
Discriminative capacity of guideline recommendations in the assessment of patients with asymptomatic microhematuria.
Kuckuck EC, Hennenlotter J, Todenhöfer T, Brünn LA, Rass GC, Stenzl A, Hakenberg OW, Roghmann F, Goebell PJ, Grimm MO, Pycha A, Bolenz C, Burger M, Benderska-Söder N, Schmitz-Dräger BJ. Kuckuck EC, et al. Among authors: schmitz drager bj. Urol Oncol. 2023 May;41(5):254.e1-254.e8. doi: 10.1016/j.urolonc.2022.08.011. Epub 2022 Oct 21. Urol Oncol. 2023. PMID: 36274029
IBCN Seminar Series 2021: Circulating tumor DNA in bladder cancer.
Christensen E, Wyatt AW, Galsky MD, Grivas P, Seiler R, Nawroth R, Goebell PJ, Schmitz-Drager BJ, Williams SB, Black PC, Kamat AM, Todenhöfer T, Dyrskjøt L. Christensen E, et al. Among authors: schmitz drager bj. Urol Oncol. 2023 Jul;41(7):318-322. doi: 10.1016/j.urolonc.2022.11.008. Epub 2022 Nov 24. Urol Oncol. 2023. PMID: 36437155 Free article. Review. No abstract available.
25 years International Bladder Cancer Network (IBCN): The past, the present, and the future.
Dyrskjøt L, Vlahou A, Black PC, Droller M, Grossmann HB, Goebell PJ, Kamat AM, Nawroth R, Seiler R, Todenhöfer T, Williams SB, Schmitz-Dräger BJ. Dyrskjøt L, et al. Among authors: schmitz drager bj. Urol Oncol. 2023 Jul;41(7):302-306. doi: 10.1016/j.urolonc.2022.10.031. Epub 2022 Nov 25. Urol Oncol. 2023. PMID: 36437158 Review.
Bladder preservation after neoadjuvant therapy - 2021 IBCN updates part 1.
Hensley PJ, Seiler R, Herr H, Mouw KW, Iyer G, Dyrskjøt L, Nawroth R, Goebell P, Schmitz-Drager B, Todenhofer T, Black PC, Kamat AM, Williams SB. Hensley PJ, et al. Urol Oncol. 2023 Jul;41(7):307-312. doi: 10.1016/j.urolonc.2023.01.001. Epub 2023 Jan 25. Urol Oncol. 2023. PMID: 36702704 Review.
Tailored immunotherapy approach with nivolumab with or without ipilimumab in patients with advanced transitional cell carcinoma after platinum-based chemotherapy (TITAN-TCC): a multicentre, single-arm, phase 2 trial.
Grimm MO, Grün CB, Niegisch G, Pichler M, Roghmann F, Schmitz-Dräger B, Baretton G, Schmitz M, Bolenz C, Foller S, Leucht K, Schumacher U, Schostak M, Meran J, Loidl W, Zengerling F. Grimm MO, et al. Lancet Oncol. 2023 Apr;24(4):347-359. doi: 10.1016/S1470-2045(23)00053-0. Epub 2023 Feb 28. Lancet Oncol. 2023. PMID: 36868252 Clinical Trial.
Simulation of the effects of molecular urine markers in follow-up of patients with high-risk non-muscle invasive bladder cancer.
Benderska-Söder N, Ecke T, Kleinlein L, Roghmann F, Bismarck E, van Rhijn BWG, Stenzl A, Witjes JA, Todenhöfer T, Hakenberg OW, Grimm MO, Goebell PJ, Burger M, Jensen JB, Schmitz-Dräger BJ. Benderska-Söder N, et al. Among authors: schmitz drager bj. Urol Oncol. 2024 Feb 24:S1078-1439(24)00041-3. doi: 10.1016/j.urolonc.2024.01.025. Online ahead of print. Urol Oncol. 2024. PMID: 38403529 Review.
Lifestyle aspects in a contemporary middle-European cohort of patients undergoing androgen deprivation therapy for advanced prostate cancer: data from the non-interventional LEAN study.
Schmitz-Dräger BJ, Bismarck E, Grammenos D, Ebert T, Starlinger R, Ottillinger B, Goebell PJ, Mühlich S, Benderska-Söder N, Hakenberg O. Schmitz-Dräger BJ, et al. Br J Nutr. 2023 Aug 14;130(3):495-502. doi: 10.1017/S0007114522003452. Epub 2022 Nov 10. Br J Nutr. 2023. PMID: 36352765 Free PMC article.
Tailored Immunotherapy Approach With Nivolumab in Advanced Transitional Cell Carcinoma.
Grimm MO, Schmitz-Dräger BJ, Zimmermann U, Grün CB, Baretton GB, Schmitz M, Foller S, Leucht K, Schostak M, Zengerling F, Schumacher U, Loidl W, Meran J. Grimm MO, et al. Among authors: schmitz drager bj. J Clin Oncol. 2022 Jul 1;40(19):2128-2137. doi: 10.1200/JCO.21.02631. Epub 2022 Mar 11. J Clin Oncol. 2022. PMID: 35275706 Clinical Trial.
120 results